Neogen Corporation Form DEFR14A: Revised definitive proxy materials
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-09-05: Form DEFR14A; Description DEFR14A; Document d449670ddefr14a.htm.
- 2007-09-05: Form DEFR14A; Description REVISED DEFINITIVE NOTICE AND PROXY STATEMENT; Document ddefr14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2017-09-05 | DEFR14A | DEFR14A | d449670ddefr14a.htm | |
| 2007-09-05 | DEFR14A | REVISED DEFINITIVE NOTICE AND PROXY STATEMENT | ddefr14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |